Relationship between adrenergic mechanisms and the analgesic effect of sodium salicylate and mefenamic acid.
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000632:Aminopyrine / Q000494:pharmacology; D000700:Analgesics / Q000494:pharmacology*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D003983:Dibenzylchlorethamine / Q000494:pharmacology; D004558:Electric Stimulation; D006145:Guanethidine / Q000494:pharmacology; D008528:Mefenamic Acid / Q000494:pharmacology; D009020:Morphine / Q000494:pharmacology; D009526:Nialamide / Q000494:pharmacology; D010643:Phenoxybenzamine / Q000494:pharmacology; D051381:Rats; D012110:Reserpine / Q000494:pharmacology; D012980:Sodium Salicylate / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D013566:Sympathomimetics / Q000494:pharmacology*; D014043:Tolazoline / Q000494:pharmacology; D062367:ortho-Aminobenzoates / Q000494:pharmacology*
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D000700:Analgesics; D000893:Anti-Inflammatory Agents; D013566:Sympathomimetics; D062367:ortho-Aminobenzoates; D000632:Aminopyrine; D010643:Phenoxybenzamine; D008528:Mefenamic Acid; D003983:Dibenzylchlorethamine; D009020:Morphine; D012110:Reserpine; D014043:Tolazoline; D009526:Nialamide; D012980:Sodium Salicylate; D006145:Guanethidine